Amneal Pharmaceuticals Inc (NASDAQ:AMRX) announced a settlement over $270 million to resolve U.S. opioid crisis-related lawsuits. The settlement includes $92.5 million in cash and $180 million in naloxone nasal spray, spread over ten years. This agreement aims to settle a significant portion of the over 900 opioid-related lawsuits against Amneal. Additionally, Amneal reported a Q1 adjusted EPS of $0.14, beating the consensus of $0.09, and sales of $659.2 million, up 8% from the previous year. The company reaffirms its FY 2024 revenue guidance of $2.55 billion-$2.65 billion and an adjusted EPS of $0.53-$0.63.